SAB Biotherapeutics, Inc. (SABS)
3.71
-0.08
(-2.11%)
USD |
NASDAQ |
Aug 31, 16:00
3.715
0.00 (0.00%)
After-Hours: 20:00
SAB Biotherapeutics Enterprise Value : 212.26M for Aug. 31, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 31, 2026 | 212.26M |
| August 28, 2026 | 218.94M |
| August 27, 2026 | 230.63M |
| August 26, 2026 | 226.45M |
| August 25, 2026 | 220.61M |
| August 24, 2026 | 204.74M |
| August 21, 2026 | 218.10M |
| August 20, 2026 | 211.42M |
| August 19, 2026 | 218.10M |
| August 18, 2026 | 218.94M |
| August 17, 2026 | 217.27M |
| August 14, 2026 | 211.42M |
| August 13, 2026 | 215.60M |
| August 12, 2026 | 219.77M |
| August 11, 2026 | 216.43M |
| August 10, 2026 | 218.10M |
| August 07, 2026 | 228.12M |
| August 06, 2026 | 223.95M |
| August 05, 2026 | 217.27M |
| August 04, 2026 | 223.95M |
| August 03, 2026 | 218.94M |
| July 31, 2026 | 200.57M |
| July 30, 2026 | 199.74M |
| July 29, 2026 | 193.06M |
| July 28, 2026 | 190.55M |
| Date | Value |
|---|---|
| July 27, 2026 | 189.72M |
| July 24, 2026 | 195.56M |
| July 23, 2026 | 201.41M |
| July 22, 2026 | 201.41M |
| July 21, 2026 | 206.41M |
| July 20, 2026 | 195.56M |
| July 17, 2026 | 198.07M |
| July 16, 2026 | 208.50M |
| July 15, 2026 | 204.74M |
| July 14, 2026 | 203.08M |
| July 13, 2026 | 213.93M |
| July 10, 2026 | 221.44M |
| July 09, 2026 | 233.13M |
| July 08, 2026 | 217.27M |
| July 07, 2026 | 228.12M |
| July 06, 2026 | 229.79M |
| July 02, 2026 | 229.79M |
| July 01, 2026 | 226.45M |
| June 30, 2026 | 228.12M |
| June 29, 2026 | 194.19M |
| June 26, 2026 | 186.61M |
| June 25, 2026 | 191.91M |
| June 24, 2026 | 189.64M |
| June 23, 2026 | 191.91M |
| June 22, 2026 | 196.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.40B |
| Oncolytics Biotech, Inc. | 100.80M |
| Sangamo Therapeutics, Inc. | 60.06M |
| Sarepta Therapeutics, Inc. | 2.479B |
| Anixa Biosciences, Inc. | 98.89M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.49M |
| Total Expenses (Quarterly) | 22.49M |
| EPS Diluted (Quarterly) | -0.282 |
| Earnings Yield | -44.75% |
| Normalized Earnings Yield | -58.72 |